-- Orthocell (ASX:OCC) said that a surgery at a military base hospital in Ohio within the US Department of Defense/Veterans Affairs hospital network was the first surgical case using its nerve repair product, Remplir, according to a Friday Australian bourse filing.
The company said that this represented an important step in its US commercialization strategy.
Abundate (SGX:570) booked a loss of SG$320,000 in the fiscal second half ended Feb. 28, from a profit of SG$134,000 a year earlier, according to a Wednesday filing with the Singapore Exchange.Loss per share stood at SG$0.0031 compared with earnings per share of SG$0.0013 in the year-ago period.Revenue rose 6% year over year to SG$4.1 million from SG$3.9 million, backed by strong demand for local construction activities.